In late December 2016, Encore Vision was acquired by Novartis with the price paid representing a major ROI for Encore Vision investors - all of whom are Angels. Encore Vision is developing a topical ophthalmic pharmaceutical treatment for presbyopia - far sightedness - directed at the cause. The pharmaceutical treatment breaks down excessive biochemical bonds within the crystalline lens that form with age and restores lens softness, thereby allowing the lens to change shape and regain focusing/accommodative ability when focusing on near objects. In-vivo proof of concept in animals has been achieved. Encore Vision had been targeting the growing estimated approximately 1.8 billion presbyope market worldwide of which approximately 100 million are in the United States. Multiple U.S. patents have been issued and multiple U.S. and foreign patent applications are pending
